SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-010220
Filing Date
2023-04-14
Accepted
2023-04-14 08:58:00
Documents
15
Period of Report
2023-04-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230413_8k.htm   iXBRL 8-K 32667
2 EXHIBIT 99.1 ex_500470.htm EX-99.1 15185
7 header.jpg GRAPHIC 16028
  Complete submission text file 0001437749-23-010220.txt   232131

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230413.xsd EX-101.SCH 4178
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230413_def.xml EX-101.DEF 14104
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230413_lab.xml EX-101.LAB 18629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230413_pre.xml EX-101.PRE 14126
9 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230413_8k_htm.xml XML 4820
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23819883
SIC: 2836 Biological Products, (No Diagnostic Substances)